Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Safety and Pharmacokinetic Characterization of Nacubactam, a Novel β-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers.

Mallalieu NL, Winter E, Fettner S, Patel K, Zwanziger E, Attley G, Rodriguez I, Kano A, Salama SM, Bentley D, Geretti AM.

Antimicrob Agents Chemother. 2020 Feb 10. pii: AAC.02229-19. doi: 10.1128/AAC.02229-19. [Epub ahead of print]

2.

Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial.

Mallalieu NL, Wimalasundera S, Hsu JC, Douglass W, Wells C, Penades IC, Cuttica R, Huppertz HI, Joos R, Kimura Y, Milojevic D, Rosenkranz M, Schikler K, Constantin T, Wouters C.

Pediatr Rheumatol Online J. 2019 Aug 22;17(1):57. doi: 10.1186/s12969-019-0364-z.

3.

Evidence of bioequivalence and positive patient user handling of a tocilizumab autoinjector.

Fettner S, Mela C, Wildenhahn F, Tavanti M, Wells C, Douglass W, Mallalieu NL.

Expert Opin Drug Deliv. 2019 May;16(5):551-561. doi: 10.1080/17425247.2019.1604678. Epub 2019 May 2.

PMID:
31043095
4.

Population Pharmacokinetic and Exposure-dizziness Modeling for a Metabotropic Glutamate Receptor Subtype 5 Negative Allosteric Modulator in Major Depressive Disorder Patients.

Cosson V, Schaedeli-Stark F, Arab-Alameddine M, Chavanne C, Guerini E, Derks M, Mallalieu NL.

Clin Transl Sci. 2018 Sep;11(5):523-531. doi: 10.1111/cts.12566. Epub 2018 Jun 27.

5.

Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.

Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, Nomura A, Lacey S, Pei J, Reiss W, Pethoe-Schramm A, Mallalieu NL, Wallace T, Michalska M, Birnboeck H, Stubenrauch K, Genovese MC.

Ann Rheum Dis. 2017 Jun;76(6):1078-1085. doi: 10.1136/annrheumdis-2016-210297. Epub 2016 Dec 22.

6.

Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Non-Michaelis-Menten P450 Kinetics on Fraction Metabolized.

Fowler S, Guerini E, Qiu N, Cleary Y, Parrott N, Greig G, Mallalieu NL.

J Pharmacol Exp Ther. 2017 Jan;360(1):164-173. Epub 2016 Nov 7.

PMID:
27821711
7.

A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]-basimglurant and absolute bioavailability after oral administration and concomitant intravenous microdose administration of [13C6]-labeled basimglurant in humans.

Guerini E, Schadt S, Greig G, Haas R, Husser C, Zell M, Funk C, Hartung T, Gloge A, Mallalieu NL.

Xenobiotica. 2017 Feb;47(2):144-153. doi: 10.3109/00498254.2016.1169334. Epub 2016 Apr 28.

PMID:
27123695
8.

Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis C.

Brennan BJ, Lemenuel-Diot A, Snoeck E, McKenna M, Solsky J, Wat C, Mallalieu NL.

Br J Clin Pharmacol. 2016 Apr;81(4):658-66. doi: 10.1111/bcp.12816. Epub 2016 Jan 8.

9.

Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor.

Mallalieu NL, Rahimy MH, Crowley CA, Appleman JR, Smith PF, Freddo JL.

Clin Ther. 2014 Dec 1;36(12):2047-2063.e3. doi: 10.1016/j.clinthera.2014.10.002. Epub 2014 Nov 4.

PMID:
25456558
10.

Identification of RO4597014, a Glucokinase Activator Studied in the Clinic for the Treatment of Type 2 Diabetes.

Qian Y, Corbett WL, Berthel SJ, Choi DS, Dvorozniak MT, Geng W, Gillespie P, Guertin KR, Haynes NE, Kester RF, Mennona FA, Moore D, Racha J, Radinov R, Sarabu R, Scott NR, Grimsby J, Mallalieu NL.

ACS Med Chem Lett. 2013 Mar 7;4(4):414-8. doi: 10.1021/ml400027y. eCollection 2013 Apr 11.

11.

Lack of age and gender effects on single-dose pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.

Mallalieu NL, Lennon S, Guy T, Liu M, Luedin E, Davies BE.

Br J Clin Pharmacol. 2009 Apr;67(4):469-72. doi: 10.1111/j.1365-2125.2009.03367.x.

12.

Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.

Mallalieu NL, Lennon S, Liu M, Kirkpatrick C, Robson R, Luedin E, Davies BE.

Antimicrob Agents Chemother. 2008 Jul;52(7):2360-6. doi: 10.1128/AAC.01249-07. Epub 2008 Apr 28.

Supplemental Content

Loading ...
Support Center